SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/52432"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/52432" > Transcriptional con...

Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4).

Yang, Tao (författare)
Vidarsson, Hilmar, 1970 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för medicinsk genetik och klinisk genetik,Institute of Biomedicine, Department of Medical and Clinical Genetics
Rodrigo Blomqvist, Sandra, 1974 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för medicinsk genetik och klinisk genetik,Institute of Biomedicine, Department of Medical and Clinical Genetics
visa fler...
Rosengren, Sally S (författare)
Enerbäck, Sven, 1958 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för medicinsk genetik och klinisk genetik,Institute of Biomedicine, Department of Medical and Clinical Genetics
Smith, Richard J H (författare)
visa färre...
 (creator_code:org_t)
Elsevier BV, 2007
2007
Engelska.
Ingår i: American journal of human genetics. - : Elsevier BV. - 0002-9297. ; 80:6, s. 1055-63
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Although recessive mutations in the anion transporter gene SLC26A4 are known to be responsible for Pendred syndrome (PS) and nonsyndromic hearing loss associated with enlarged vestibular aqueduct (EVA), also known as "DFNB4," a large percentage of patients with this phenotype lack mutations in the SLC26A4 coding region in one or both alleles. We have identified and characterized a key transcriptional regulatory element in the SLC26A4 promoter that binds FOXI1, a transcriptional activator of SLC26A4. In nine patients with PS or nonsyndromic EVA, a novel c.-103T-->C mutation in this regulatory element interferes with FOXI1 binding and completely abolishes FOXI1-mediated transcriptional activation. We have also identified six patients with mutations in FOXI1 that compromise its ability to activate SLC26A4 transcription. In one family, the EVA phenotype segregates in a double-heterozygous mode in the affected individual who carries single mutations in both SLC26A4 and FOXI1. This finding is consistent with our observation that EVA occurs in the Slc26a4(+/-); Foxi1(+/-) double-heterozygous mouse mutant. These results support a novel dosage-dependent model for the molecular pathogenesis of PS and nonsyndromic EVA that involves SLC26A4 and its transcriptional regulatory machinery.

Nyckelord

Alleles
Amino Acid Sequence
Animals
Binding Sites
COS Cells
Cercopithecus aethiops
Conserved Sequence
Electrophoretic Mobility Shift Assay
Female
Forkhead Transcription Factors
chemistry
genetics
metabolism
Genes
Reporter
Genetic Screening
Hearing Loss
diagnosis
genetics
Heterozygote
Humans
Luciferases
metabolism
Membrane Transport Proteins
genetics
Mice
Models
Genetic
Molecular Sequence Data
Mutation
Pedigree
Promoter Regions (Genetics)
Protein Binding
Protein Structure
Tertiary
Sequence Homology
Amino Acid
Siblings
Syndrome
Trans-Activators
chemistry
genetics
metabolism
Transcription
Genetic
Vestibular Aqueduct
pathology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy